Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
$3.62
-3.5%
$5.32
$3.39
$16.00
$39.20M0.8754,023 shs62,597 shs
Kronos Bio, Inc. stock logo
KRON
Kronos Bio
$0.69
-0.2%
$0.79
$0.65
$1.60
$41.91M1.75309,158 shs506,947 shs
NightHawk Biosciences, Inc. stock logo
NHWK
NightHawk Biosciences
$0.39
$0.26
$1.16
$10.78M0.1997,242 shs173,100 shs
Rein Therapeutics, Inc. stock logo
RNTX
Rein Therapeutics
$2.00
-2.4%
$1.79
$1.35
$4.40
$44.31M1.7853,984 shs148,425 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
0.00%-6.25%-21.55%-48.13%-71.37%
Kronos Bio, Inc. stock logo
KRON
Kronos Bio
0.00%+2.33%-19.07%-29.65%-8.87%
NightHawk Biosciences, Inc. stock logo
NHWK
NightHawk Biosciences
0.00%0.00%0.00%0.00%0.00%
Rein Therapeutics, Inc. stock logo
RNTX
Rein Therapeutics
0.00%-4.65%+7.33%-5.53%+204,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
3.4914 of 5 stars
4.45.00.00.00.61.71.3
Kronos Bio, Inc. stock logo
KRON
Kronos Bio
2.4651 of 5 stars
3.23.00.00.00.63.31.3
NightHawk Biosciences, Inc. stock logo
NHWK
NightHawk Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Rein Therapeutics, Inc. stock logo
RNTX
Rein Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
2.83
Moderate Buy$33.00811.60% Upside
Kronos Bio, Inc. stock logo
KRON
Kronos Bio
2.33
Hold$1.63136.40% Upside
NightHawk Biosciences, Inc. stock logo
NHWK
NightHawk Biosciences
0.00
N/AN/AN/A
Rein Therapeutics, Inc. stock logo
RNTX
Rein Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NHWK, RNTX, AVTX, and KRON Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/25/2025
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageUnderperform ➝ Buy$23.00
3/25/2025
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$36.00
3/20/2025
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
3/20/2025
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$18.00
2/28/2025
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$48.00
(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
$441K88.88N/AN/A$9.11 per share0.40
Kronos Bio, Inc. stock logo
KRON
Kronos Bio
$9.19M4.56N/AN/A$2.73 per share0.25
NightHawk Biosciences, Inc. stock logo
NHWK
NightHawk Biosciences
$6.38M0.00N/AN/A$2.82 per share0.00
Rein Therapeutics, Inc. stock logo
RNTX
Rein Therapeutics
N/AN/AN/AN/A$1.41 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
-$31.54MN/A0.00N/AN/AN/A-442.16%122.99%8/11/2025 (Estimated)
Kronos Bio, Inc. stock logo
KRON
Kronos Bio
-$112.67M-$1.07N/AN/AN/A-867.66%-64.55%-48.18%8/14/2025 (Estimated)
NightHawk Biosciences, Inc. stock logo
NHWK
NightHawk Biosciences
-$43.44M-$1.99N/AN/AN/A-2,333.27%-91.62%-56.48%N/A
Rein Therapeutics, Inc. stock logo
RNTX
Rein Therapeutics
-$15.73M-$2.86N/AN/AN/AN/A-74.08%-27.93%N/A

Latest NHWK, RNTX, AVTX, and KRON Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Rein Therapeutics, Inc. stock logo
RNTX
Rein Therapeutics
-$0.21-$0.25-$0.04-$0.25N/AN/A
5/12/2025Q1 2025
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
-$1.07-$1.25-$0.18-$1.25N/AN/A
4/7/2025Q4 2024
Rein Therapeutics, Inc. stock logo
RNTX
Rein Therapeutics
N/A-$0.26N/A-$1.89N/AN/A
3/18/2025Q4 2024
Kronos Bio, Inc. stock logo
KRON
Kronos Bio
-$0.30-$0.43-$0.13-$0.43$1.00 million$2.27 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
N/AN/AN/AN/AN/A
Kronos Bio, Inc. stock logo
KRON
Kronos Bio
N/AN/AN/AN/AN/A
NightHawk Biosciences, Inc. stock logo
NHWK
NightHawk Biosciences
N/AN/AN/AN/AN/A
Rein Therapeutics, Inc. stock logo
RNTX
Rein Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
N/A
1.42
1.42
Kronos Bio, Inc. stock logo
KRON
Kronos Bio
N/A
8.32
8.32
NightHawk Biosciences, Inc. stock logo
NHWK
NightHawk Biosciences
0.27
0.99
0.99
Rein Therapeutics, Inc. stock logo
RNTX
Rein Therapeutics
N/A
3.30
3.30

Institutional Ownership

CompanyInstitutional Ownership
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
87.06%
Kronos Bio, Inc. stock logo
KRON
Kronos Bio
64.09%
NightHawk Biosciences, Inc. stock logo
NHWK
NightHawk Biosciences
21.16%
Rein Therapeutics, Inc. stock logo
RNTX
Rein Therapeutics
90.89%

Insider Ownership

CompanyInsider Ownership
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
3.03%
Kronos Bio, Inc. stock logo
KRON
Kronos Bio
24.40%
NightHawk Biosciences, Inc. stock logo
NHWK
NightHawk Biosciences
15.90%
Rein Therapeutics, Inc. stock logo
RNTX
Rein Therapeutics
5.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
4010.83 million10.37 millionNot Optionable
Kronos Bio, Inc. stock logo
KRON
Kronos Bio
10060.97 million45.62 millionOptionable
NightHawk Biosciences, Inc. stock logo
NHWK
NightHawk Biosciences
7726.08 million21.94 millionOptionable
Rein Therapeutics, Inc. stock logo
RNTX
Rein Therapeutics
922.15 million20.56 millionN/A

Recent News About These Companies

Rein Therapeutics Inc. (RNTX)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Avalo Therapeutics stock logo

Avalo Therapeutics NASDAQ:AVTX

$3.62 -0.13 (-3.47%)
Closing price 04:00 PM Eastern
Extended Trading
$3.79 +0.17 (+4.70%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Kronos Bio stock logo

Kronos Bio NASDAQ:KRON

$0.69 +0.00 (+0.19%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.

NightHawk Biosciences stock logo

NightHawk Biosciences NYSE:NHWK

NightHawk Biosciences, Inc., an integrated biopharmaceutical company, develops, manufactures, and commercializes medical countermeasures that combat unmet and emerging biothreats. The company develops ANTHIM (obiltoxaximab), a monoclonal antibody antitoxin for the treatment of inhalational anthrax. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.

Rein Therapeutics stock logo

Rein Therapeutics NASDAQ:RNTX

$2.00 -0.05 (-2.44%)
As of 04:00 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.